Demographic and clinical parameters
| |
Age, years, Na
|
148
|
36
|
59
| | |
Mean ± SD
|
54.3 ± 12.0
|
58.4 ± 9.5
|
61.6 ± 9.7
|
Median, Q1 to Q3
|
55.0, 46.0 to 63.5
|
58.5, 52.5 to 63.5
|
62.0, 56.0 to 68.0
|
Minimum, maximum
|
26.0, 78.0
|
43.0, 80.0
|
33.0, 80.0
|
Gender, n
|
148
|
36
|
60
| | |
Male, n (%)
|
18 (12.2)
|
6 (16.7)
|
12 (20.0)
|
Female, n (%)
|
130 (87.8)
|
30 (83.3)
|
48 (80.0)
|
WHO FC, N
|
139
|
34
|
60
| |
<0.05
|
I/II, n (%)
|
127 (91.4)
|
28 (82.4)
|
37 (61.7)
|
III/IV, n (%)
|
12 (8.6)
|
6 (17.6)
|
23 (38.3)
|
6-minute walk distance, N
|
108
|
27
|
48
| | |
Mean ± SD
|
422.4 ± 110.4
|
397.4 ± 102.3
|
391.4 ± 109.8
|
Median, Q1 to Q3
|
432.5, 364.5 to 502.0
|
414.5, 341.0 to 472.0
|
395.0, 318.0 to 460.5
|
SSc disease duration (years), N
|
147
|
36
|
60
| | |
Mean ± SD
|
11.0 ± 8.0
|
10.0 ± 5.0
|
14.0 ± 12.0
|
Median, Q1 to Q3
|
8.0, 5.0 to 13.0
|
9.0, 6.0 to 15.0
|
11.0, 6.0 to 16.0
|
SSc subtype, N
|
146
|
36
|
59
| | |
Limited, n (%)
|
90 (61.6)
|
20 (55.6)
|
44 (74.6)
|
Diffuse, n (%)
|
45 (30.8)
|
13 (36.1)
|
10 (16.9)
|
Overlap/mixed CTD, n (%)
|
11 (7.5)
|
3 (8.3)
|
5 (8.5)
|
Presence of peripheral edema, n/N (%)
|
8/147 (5.4)
|
7/36 (19.4)
|
11/60 (18.3)
|
<0.01
| |
Presence of telangiectasias, n/N (%)
|
108/148 (73.0)
|
22/36 (61.1)
|
52/60 (86.7)
| |
<0.005
|
FVC % predicted, N
|
148
|
36
|
60
| | |
Mean ± SD
|
92.5 ± 17.6
|
88.7 ± 14.5
|
92.0 ± 19.7
|
Median, Q1-Q3
|
91.9, 79.9 to 102.7
|
87.1, 80.0 to 96.5
|
89.5, 77.2 to 102.5
|
FVC % predicted /DLCO % predicted, N
|
148
|
36
|
60
| |
<0.01
|
Mean ± SD
|
1.9 ± 0.4
|
1.9 ± 0.4
|
2.3 ± 0.7
|
Median, Q1 to Q3
|
1.8, 1.5 to 2.1
|
2.0, 1.5 to 2.2
|
2.2, 1.8 to 2.5
|
TLC % predicted, N
|
127
|
28
|
54
|
<0.05
| |
Mean ± SD
|
92.8 ± 21.9
|
84.8 ± 14.4
|
88.1 ± 21.6
| |
Median, Q1 to Q3
|
92.5, 80.0 to 106.0
|
83.0, 74.0 to 95.0
|
87.3, 78.0 to 100.3
| |
Serum laboratory tests
| |
Presence of anti-centromere antibodies
| | | | |
<0.05
|
n/N (%)
|
49/141 (34.8)
|
10/34 (29.4)
|
30/56 (53.6)
|
Log10 NT-proBNP (pg/ml), N
|
141
|
34
|
56
|
<0.05
| |
Mean ± SD
|
2.0 ± 0.5
|
2.2 ± 0.5
|
2.4 ± 0.5
|
Median, Q1 to Q3
|
2.1, 1.7 to 2.3
|
2.2, 1.9 to 2.5
|
2.3, 2.0 to 2.8
|
Serum urate, mg/100 ml, N
|
141
|
34
|
56
| |
<0.01
|
Mean ± SD
|
4.7 ± 1.4
|
4.7 ± 1.3
|
5.6 ± 1.4
|
Median, Q1 to Q3
|
4.4, 3.7 to 5.3
|
4.5, 3.7 to 5.4
|
5.6, 4.6 to 6.5
|
Log10 estimated GFR
|
141
|
34
|
55
| | |
1.9 ± 0.1
|
1.9 ± 0.1
|
1.9 ± 0.1
|
1.9, 1.9 to 2.0
|
1.9, 1.8 to 2.0
|
1.9, 1.8 to 2.0
|
Echocardiography
| |
Left atrium diameter, mm, N
|
148
|
36
|
60
|
<0.001
| |
Mean ± SD
|
30.2 ± 5.1
|
33.9 ± 3.6
|
31.8 ± 5.4
|
Median, Q1 to Q3
|
31.0, 27.8 to 34.0
|
33.5, 31.0 to 37.0
|
32.0, 30.0 to 36.0
|
Right atrium area, cm2, N
|
142
|
33
|
58
| |
<0.05
|
Mean ± SD
|
12.8 ± 4.7
|
14.7 ± 5.9
|
16.8 ± 5.8
|
Median, Q1 to Q3
|
12.0, 10.0 to 14.3
|
12.4, 10.5 to 18.0
|
15.8, 13.4 to 20.0
|
TAPSE (mm), N
|
138
|
33
|
53
| | |
Mean ± SD
|
23.2 ± 4.3
|
23.8 ± 5.1
|
21.1 ± 4.3
|
Median, Q1 to Q3
|
23.7, 20.4 to 26.0
|
23.0, 20.0 to 27.0
|
20.8, 19.0 to 23.0
|
TR velocity (m/s), N
|
140
|
35
|
58
|
<0.001
|
<0.05
|
Mean ± SD
|
2.3 ± 0.4
|
2.7 ± 0.3
|
3.0 ± 0.7
|
Median, Q1 to Q3
|
2.3, 2.2 to 2.6
|
2.7, 2.5 to 2.9
|
2.9, 2.5 to 3.5
|
Electrocardiography
| |
Presence of right axis deviation, n/N (%)
|
2/138 (1.4)
|
1/30 (3.3)
|
8/58 (13.8)
| | |
Right heart catheterization
| |
PAWP, mmHg, N
|
148
|
36
|
60
|
<0.001
| |
Mean ± SD
|
7.7 ± 3.3
|
10.8 ± 3.0
|
9.9 ± 3.3
|
Median, Q1 to Q3
|
8.0, 5.0 to 10.0
|
11.0, 9.0 to 13.0
|
10.5, 7.5 to 12.5
|
TPG, mmHg, N
|
148
|
36
|
60
|
<0.001
|
<0.001
|
Mean ± SD
|
7.9 ± 2.7
|
11.6 ± 2.8
|
22.3 ± 9.7
|
Median, Q1 to Q3
|
7.0, 6.0 to 10.0
|
11.0, 10.0 to 13.0
|
20.0, 15.0 to 28.0
|
DWG, mmHg, N
|
148
|
36
|
60
| |
<0.001
|
Mean ± SD
|
1.8 ± 2.7
|
3.0 ± 5.4
|
10.7 ± 8.1
|
Median, Q1 to Q3
|
1.0, 0.0 to 3.0
|
2.0, 0.5 to 5.0
|
8.0, 5.0 to 17.0
|
PVR, dyn.sec/cm5, N
|
148
|
36
|
60
|
<0.001
|
<0.001
|
Mean ± SD
|
128.0 ± 50.8
|
179.8 ± 58.7
|
375.8 ± 217.0
|
Median, Q1 to Q3
|
121.5, 91.3 to 153.9
|
170.3, 147.8 to 187.8
|
295.5, 236.0 to 419.1
|